-
公开(公告)号：US20240352152A1
公开(公告)日：2024-10-24
申请号：US18633379
申请日：2024-04-11
CPC分类号： C07K16/40 , A61P27/02 , A61P35/04 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
-
2.发明公开公开(公告)号：US20240076408A1
公开(公告)日：2024-03-07
申请号：US18312891
申请日：2023-05-05
IPC分类号： C07K16/40 , A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US10736960B2
公开(公告)日：2020-08-11
申请号：US15399524
申请日：2017-01-05
IPC分类号： A61K39/395 , A61P13/12 , C07K16/40 , A61K39/00
摘要： In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
4.发明申请公开(公告)号：US20190127484A1
公开(公告)日：2019-05-02
申请号：US16131871
申请日：2018-09-14
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
-
5.发明申请公开(公告)号：US20180291111A1
公开(公告)日：2018-10-11
申请号：US15909423
申请日：2018-03-01
IPC分类号： C07K16/40
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20170355777A1
公开(公告)日：2017-12-14
申请号：US15615588
申请日：2017-06-06
IPC分类号： C07K16/30 , G01N33/574 , A61K47/68
CPC分类号： C07K16/3092 , A61K47/6859 , A61K47/6869 , C07K14/4727 , C07K16/3015 , C07K2317/34 , C07K2317/56 , C07K2317/565 , G01N33/57438 , G01N33/57449 , G01N33/57492 , G01N2333/4725
摘要： In various embodiments the invention provides anti-mucin-like protein (MLP) monoclonal antibodies, compositions and methods for detecting MLP as a biomarker for mucin-secreting type of cancer such as ovarian or pancreatic cancer.
-
7.发明申请Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation 审中-公开用于治疗与MASP-2依赖性补体激活相关的病症的方法公开(公告)号：US20140056873A1
公开(公告)日：2014-02-27
申请号：US13790756
申请日：2013-03-08
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
摘要翻译： 一方面，本发明提供抑制活体受试者中MASP-2依赖性补体活化的作用的方法。 所述方法包括向有需要的受试者施用一定量的有效抑制MASP-2依赖性补体活化的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时保持免疫系统的经典（C1q依赖）途径组分完整。 在另一方面，本发明提供了用于抑制凝集素依赖性补体活化的作用的组合物，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。
-
8.发明申请Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders 审中-公开抑制MASP-1和/或MASP-2和/或MASP-3用于治疗各种疾病和障碍的组合物和方法公开(公告)号：US20130344073A1
公开(公告)日：2013-12-26
申请号：US13921139
申请日：2013-06-18
IPC分类号： C07K16/40 , A61K39/395 , A61K45/06
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
摘要翻译： 一方面，本发明提供用于抑制患有或处于发展中的疾病或疾病的受试者中的MASP-3依赖性补体活化的方法和组合物，所述疾病或病症选自阵发性夜间血红蛋白尿，年龄相关性黄斑变性， 关节炎，弥漫性血管内凝血，血栓性微血管病变，哮喘，致密沉积病，波氏免疫坏死性新月体性肾小球肾炎，创伤性脑损伤，吸入性肺炎，眼内炎，眼科神经性眼炎和白塞病，通过向受试者施用包含一定量的MASP- 3抑制剂以有效抑制MASP-3依赖性补体活化的量。 在一些实施方案中，给予受试者MASP-2抑制剂和MASP-1抑制剂，MASP-2抑制剂，MASP-2抑制剂和MASP-3抑制剂，MASP-3抑制剂和MASP-1抑制剂 ，或MASP-1抑制剂，MASP-2抑制剂和MASP-3抑制剂。
-
公开(公告)号：US20130266560A1
公开(公告)日：2013-10-10
申请号：US13830831
申请日：2013-03-14
IPC分类号： C07K16/40 , A61K45/06 , A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/54 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12005117B2
公开(公告)日：2024-06-11
申请号：US16917157
申请日：2020-06-30
IPC分类号： A61P13/12 , A61K39/395 , C07K16/40 , A61K39/00
CPC分类号： A61K39/3955 , A61K39/395 , A61P13/12 , C07K16/40 , A61K2039/505 , A61K2121/00 , C07K2317/21 , C07K2317/34 , C07K2317/54 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.075 秒)
